The FDA Center for Biologics Evaluation and Research (CBER) is dedicated to ensuring the safety, purity, and potency of biological therapeutics, including vaccines, gene therapies, blood products, and advanced cell-based treatments. Its mission centers on advancing regulatory science through cutting...
The FDA Center for Biologics Evaluation and Research (CBER) is dedicated to ensuring the safety, purity, and potency of biological therapeutics, including vaccines, gene therapies, blood products, and advanced cell-based treatments. Its mission centers on advancing regulatory science through cutting-edge laboratory capabilities, diagnostic innovation, and rigorous quality assurance systems. Strategic priorities include modernizing analytical platforms for biologics characterization, supporting the development of novel in-vitro diagnostics, and maintaining accredited reference material production. CBER actively invests in automation for nucleic acid processing, precision instrumentation for molecular analysis, and specialized reagents to support complex biological assays such as ELISA and single-cell multiomics.
CBER’s procurement patterns reflect a heavy reliance on high-precision laboratory instrumentation, specialized reagents, and maintenance services for critical scientific equipment. The agency frequently seeks analytical instruments, automated extraction systems, and PCR platforms essential for biologics testing and research. Contract structures typically involve combined solicitations and sources-sought notices to foster early industry engagement and technical alignment, often targeting vendors with deep expertise in life science instrumentation and compliance-driven service networks.
CBER primarily targets NAICS codes related to analytical laboratory instrument manufacturing and biological product manufacturing, with strong emphasis on diagnostic reagents and precision equipment repair. The agency demonstrates a clear preference for Small Business Administration (SBA) set-asides, particularly for maintenance and specialized service contracts, indicating a commitment to fostering small, niche suppliers with niche technical capabilities. Vendor relationships are built around proven compliance with GMP, GLP, and ISO standards, with a preference for firms capable of supporting regulated laboratory environments.
CBER operates under the Food and Drug Administration within the Department of Health and Human Services, with a mission-focused structure centered on scientific evaluation and regulatory oversight. It utilizes a mix of direct procurement, indefinite-delivery/indefinite-quantity (IDIQ) vehicles, and competitive solicitations to acquire specialized scientific and technical services essential to its regulatory mandate. Its geographic footprint is centralized within FDA’s broader biologics evaluation infrastructure, with operations aligned to federal laboratory standards and quality systems.
